MicroRNA-451 in chronic myeloid leukemia: miR-451–BCR-ABL regulatory loop?

Lopotová, Tereza; Žáčková, Markéta; Klamová, Hana; Moravcová, Jana

doi:10.1016/j.leukres.2011.03.029

Cited by 65 publications

(43 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, plasma miR-451a expression was found to decrease dramatically in different phases of CML. miR-451a may have regulatory roles in pathogenesis and imatinib resistance in patients with CML [15][16][17]. To further examine the possible roles of miRNAs in CML patients, we investigated plasma miRNA expression profiles at different stages of CML, which may shed light on the mechanisms involved in the progression of CML.…”

Section: Research Papermentioning

confidence: 99%

“…miR-451a decreased dramatically during the progression, which is related to CML pathogenesis and may reflect a transformation from the chronic to accelerated phases and blast crisis. Lopotová T et al found that miR-451a was down-regulated in CML patients compared to healthy controls, and a complex relationship between miR-451a and BCR-ABL was revealed in CML [17]. Down-regulated miR-451a was observed in imatinib-resistant CML cases in which miR-451a and MYC formed a regulatory loop that may be a potential therapeutic target for CML [15].…”

Section: Oncotarget S474 Wwwimpactjournalscom/oncotargetmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Zhang¹,

Jiang²,

Han³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

ABSTRACTmicroRNAs play important regulatory roles in hematologic malignancies, and dysregulation of circulating miRNAs serves as diagnostic, prognostic and predictive biomarkers in many diseases. The correlation of plasma miRNA profiles with the progression of chronic myeloid leukemia (CML) has not been investigated. We have applied microarrays to identify differentially expressed miRNAs, followed by qRT-PCR to validate candidate miRNAs from four sample pools including chronic phase (CP), accelerated phase(AP), blast crisis(BC) and healthy control. Clustering analyses revealed varying phase-specific patterns of plasma miRNA expression during CML progression. Different phases of CML showed differential expression profiles between sample pools during the progression. The functional annotation tool, DAVID, found that putative targets of dysregulated miRNAs in different phases of diease are involved in several important signaling pathways. Gradually decreased expression levels of miR-451a were validated in CML patients from the CP to AP and BC; when CML patients achieved major molecular response (MMR), miR-451a expression was increased and restored to normal range. These data provide an important resource for studies on CML progression and allow a better understanding of the fundamental differences in plasma miRNA expression profiles among the different phases of CML.

show abstract

Section: Research Papermentioning

confidence: 99%

Section: Oncotarget S474 Wwwimpactjournalscom/oncotargetmentioning

confidence: 99%

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Zhang¹,

Jiang²,

Han³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Furthermore, high expression of miRNA-146a impaired bone marrow reconstitution in mice and reduced survival of hematopoietic stem cells. Treatment of AML patients with ATRA results in downregulation of miRNA-146a, which is associated with upregulation of Smad4 pathway [43,66]. miRNA-146a is downregulated in MLL rearrangements.…”

Section: Mirna-29mentioning

confidence: 99%

Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia

Klimenko¹

2018

Myeloid Leukemia

View full text Add to dashboard Cite

Small non-coding RNAs (sncRNAs) are small regulatory molecules, which play key roles in fine-tune of all cell functions. In late 1970s and early 1980s, it was first determined that non-coding RNAs contribute to the cellular regulatory processes. The kingdom of sncRNAs is very numerous and it is clear that functions of different members of this family is different from each other and may be involved in normal and pathologic processes in cell. Recently it was investigated that sncRNAs and long non-coding RNAs play roles in cellular differentiation, proliferation, metabolic processes, bioenergetic regulation, cell death and inter-cellular communications, etc. In embryos, non-coding RNAs control maternal-zygotic transition, the maintenance of pluripotency, the pattering of the body axes, the specification and differentiation of cell types and morphogenesis of organs. Development of hematologic malignancies in humans, their course and regulation of resistance and sensitivity of tumorous cells to therapy are under the control of sncRNAs.

show abstract

“…Besides, miR-224 expression correlated with AML subtypes, in particular the t(15,17) rearrangement, a molecular predictor of favorable clinical outcome [151]. There were additional miRNAs implicated as chemoresistance biomarkers reported in hematological malignancies [152][153][154][155][156][157][158][159][160][161][162].…”

Section: Translating Mirnas Into Clinical Applications In Hematologicmentioning

confidence: 99%

Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies

Xie

Jing

et al. 2015

Blood Reviews

View full text Add to dashboard Cite

MicroRNA-451 in chronic myeloid leukemia: miR-451–BCR-ABL regulatory loop?

Cited by 65 publications

References 8 publications

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia

Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies

Contact Info

Product

Resources

About